Bariatric surgery provides profound metabolic benefits beyond mere weight reduction. Specifically, metabolic procedures modify systemic lipid metabolism and reduce long-term cardiovascular mortality. Traditional lipid panels often fail to capture the true burden of atherogenic particles in circulation. Consequently, clinicians increasingly measure circulating apolipoprotein concentrations to assess residual vascular risk. The ApoB ApoA1 ratio serves as an exceptional biomarker for evaluating cardiovascular disease risk. However, evidence regarding the durable effects of sleeve gastrectomy on this ratio has remained scarce. A landmark prospective cohort study now demonstrates that sleeve gastrectomy drives lasting improvements in apolipoprotein profiles over a ten-year timeline.

Cardiometabolic Significance of the ApoB ApoA1 Ratio

Apolipoprotein B represents the primary structural protein embedded within atherogenic lipoproteins, including low-density lipoprotein, intermediate-density lipoprotein, and very-low-density lipoprotein particles. Therefore, serum ApoB directly quantifies the total number of circulating atherogenic particles. Conversely, apolipoprotein A1 constitutes the principal protein component of high-density lipoprotein particles. This protective molecule mediates reverse cholesterol transport, which extracts excess cholesterol from peripheral arterial walls and transports it back to the liver.

Because of these opposing physiological roles, the balance between ApoB and ApoA1 reflects the net equilibrium between pro-atherogenic and anti-atherogenic forces. Epidemiological investigations demonstrate that this ratio surpasses conventional low-density lipoprotein cholesterol in predicting incident myocardial infarction. Patients with severe obesity frequently exhibit atherogenic dyslipidemia characterized by elevated ApoB and depressed ApoA1 concentrations. Furthermore, systemic insulin resistance and visceral adiposity disrupt hepatic lipoprotein synthesis. Sleeve gastrectomy radically alters gastrointestinal anatomy and neurohormonal signaling. Thus, examining apolipoprotein trajectories following metabolic surgery offers crucial insights into long-term cardiovascular risk reduction.

Study Design and Longitudinal Cohort Evaluation

To evaluate these biochemical changes, researchers conducted a comprehensive prospective observational cohort study. The investigation enrolled adult patients with severe obesity undergoing elective sleeve gastrectomy at a specialized academic medical center. Investigators collected standardized fasting blood samples at baseline and at predefined postoperative intervals.

The initial analysis examined 376 consecutive participants who completed comprehensive clinical assessments at baseline and one year postoperatively. In addition, the researchers established an extended follow-up cohort comprising 131 participants monitored between three and ten years post-surgery. The long-term cohort achieved a mean follow-up duration of 5.7 ± 2.5 years. Through rigorous laboratory assays, investigators measured circulating levels of ApoA1 and ApoB. Furthermore, they calculated the resulting apolipoprotein ratio across all time points. Statistical models utilized adjusted means with 95% confidence intervals to evaluate longitudinal trajectories. This robust design enabled clinicians to differentiate short-term metabolic shifts from durable, long-term cardiovascular adaptations following surgical intervention.

Sustained Reductions in the Atherogenic Index

The prospective investigation demonstrated a profound, progressive reduction in the ApoB ApoA1 ratio across the entire study timeline. At baseline, participants exhibited an elevated adjusted mean ratio of 0.68. This elevated initial value reflected a high baseline burden of atherogenic particles relative to protective high-density lipoproteins.

Following surgical intervention, the adjusted mean ratio decreased significantly to 0.61 at one year post-surgery. Furthermore, this favorable trajectory continued to improve during extended surveillance. The adjusted mean ratio reached 0.55 between three and five years postoperatively. Most notably, the ratio stabilized at 0.54 among patients evaluated beyond five years of follow-up. Consequently, surgical intervention induced a durable reduction in atherogenic particle balance that persisted for up to a decade. These statistical findings confirm that metabolic remodeling after sleeve gastrectomy provides sustained cardiovascular protection. Therefore, clinicians can expect durable improvements in atherogenic risk indices even when patients experience minor weight plateaus during late postoperative phases.

Temporal Trends in ApoA1 and ApoB Concentrations

Analyzing the individual apolipoprotein components revealed distinct physiological trajectories over time. Most remarkably, serum ApoA1 concentrations displayed a continuous, statistically significant upward trajectory throughout the entire ten-year evaluation period. Baseline ApoA1 levels averaged 152.47 mg/dL among study participants. Following surgery, mean ApoA1 concentrations increased to 168.69 mg/dL at one year. Subsequently, levels rose to 177.99 mg/dL between three and five years, reaching an impressive 184.24 mg/dL beyond five years.

In contrast, ApoB concentrations exhibited a distinct, non-linear pattern over the postoperative period. Baseline ApoB levels averaged 100.44 mg/dL before surgical intervention. Between three and five years post-surgery, ApoB concentrations decreased significantly to 93.53 mg/dL. However, this absolute reduction did not persist during extended surveillance beyond five years, where ApoB levels adjusted to 97.86 mg/dL. Nevertheless, the substantial and sustained elevation in ApoA1 successfully preserved a markedly favorable ratio. Hence, sustained reverse cholesterol transport capacity drove long-term atheroprotection.

Clinical Implications for Cardiometabolic Risk Management

These longitudinal findings hold vital practical implications for physicians managing patients with severe obesity and cardiometabolic disorders. First, traditional lipid assessments such as total cholesterol and low-density lipoprotein cholesterol may overlook persistent improvements in reverse cholesterol transport. Therefore, measuring apolipoproteins provides a more accurate assessment of residual cardiovascular risk following metabolic surgery.

Second, the gradual rebound of ApoB concentrations beyond five years highlights the necessity of lifelong clinical surveillance. Although surgical anatomy facilitates sustained weight reduction, subtle changes in lifestyle, dietary patterns, or age-related vascular biology can gradually elevate circulating atherogenic particles. Consequently, multidisciplinary teams must monitor complete lipid panels annually. When ApoB concentrations climb during late follow-up, clinicians should consider evidence-based pharmacotherapies, such as statins or ezetimibe, to optimize cardiovascular prevention. In conclusion, combining metabolic surgery with vigilant long-term medical follow-up ensures maximal reduction in cardiovascular morbidity.

Frequently Asked Questions

Why is the ApoB ApoA1 ratio a superior cardiovascular marker?

The ratio evaluates the balance between atherogenic particles and anti-atherogenic lipoproteins. Apolipoprotein B measures the exact particle number of all harmful lipoproteins, including low-density and very-low-density lipoproteins. Meanwhile, apolipoprotein A1 reflects protective high-density lipoproteins that remove cholesterol from vascular tissues. Consequently, this calculated metric provides superior prognostic accuracy for coronary artery disease compared to standard low-density lipoprotein cholesterol measurements alone.

Why did ApoB concentrations rebound beyond five years post-surgery?

ApoB levels initially dropped due to rapid caloric restriction and acute reduction in hepatic lipid synthesis. Over time, modest weight regain, dietary changes, and natural age-related hepatic adaptations can stimulate apolipoprotein B synthesis. However, because ApoA1 levels continued to rise, the overall cardiovascular risk balance remained highly favorable. Nevertheless, clinicians must maintain routine surveillance to detect late elevations in atherogenic particles.

How should clinicians monitor lipid profiles after sleeve gastrectomy?

Clinicians should perform comprehensive annual metabolic assessments that include advanced lipid testing alongside traditional lipid panels. Tracking both apolipoprotein B and apolipoprotein A1 allows physicians to quantify residual atherogenic risk accurately. If ApoB levels elevate during extended follow-up, physicians should reinforce dietary counseling and initiate lipid-lowering therapies to preserve long-term cardiometabolic benefits achieved through metabolic surgery.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Please note that the guidelines or clinical practices mentioned in this content may vary according to regions, countries, and medical associations. Refer to the latest local and national guidelines for clinical practice.

References

1. Martínez-Montoro JI et al. Effects of bariatric surgery on apolipoprotein A1, apolipoprotein B, and apolipoprotein B/ apolipoprotein A1 ratio: Findings from a prospective cohort. Eur J Intern Med. 2026 Aug 22. doi: undefined. PMID: 42632777.
2. Al Shawaf E, Al-Ozairi E, Al-Asfar F, Mohammad A, Al-Beloushi S, Devarajan S, et al. Atherogenic index of plasma (AIP) a tool to assess changes in cardiovascular disease risk post laparoscopic sleeve gastrectomy. J Clin Med. 2023;12(4):1542.
3. Happonen N, Taskinen MR, Westerbacka J, et al. Glycated apolipoprotein B decreases after bariatric surgery in people with and without diabetes: a potential contribution to reduction in cardiovascular risk. Atherosclerosis. 2022;346:10-17.